Murphy, Leigh - University of Manitoba - Department of Biochemistry and Medical Genetics

研究领域

Mechanism of action of hormones in human breast cancer. Molecular mechanisms of anti-estrogen and progestin resistance in human breast cancer. Biomarkers of risk and progression of breast cancer. Biospecimen banking as a research resource

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

A 10-Gene Yin Yang Expression Ratio Signature for Stage IA and IB Non-Small Cell Lung Cancer. Xu W, Jia G, Davie JR, Murphy L, Kratzke R, Banerji S. J Thorac Oncol. 2016 Aug 4. pii: S1556-0864(16)30702-X. doi: 10.1016/j.jtho.2016.07.023. [Epub ahead of print] Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymes. Wang J, Duan Z, Nugent Z, Zou JX, Borowsky AD, Zhang Y, Tepper CG, Li JJ, Fiehn O, Xu J, Kung HJ, Murphy LC, Chen HW. Cancer Lett. 2016 Aug 10;378(2):69-79. doi: 10.1016/j.canlet.2016.05.004. Epub 2016 May 6. Parental Decision Making Regarding the Disclosure or Nondisclosure of a Mutation-Positive BRCA1/2 Test Result to Minors. Seenandan-Sookdeo KA, Hack TF, Lobchuk M, Murphy L, Marles S. Oncol Nurs Forum. 2016 May 1;43(3):330-41. doi: 10.1188/16.ONF.330-341. Regulation of steroid hormone receptors and coregulators during the cell cycle highlights potential novel function in addition to roles as transcription factors. Zheng Y, Murphy LC. Nucl Recept Signal. 2016 Jan 13;14:e001. doi: 10.1621/nrs.14001. eCollection 2016. Review. The steroid receptor RNA activator protein (SRAP) controls cancer cell migration/motility. Yan Y, Cooper C, Hamedani MK, Guppy B, Xu W, Tsuyuki D, Zhang C, Nugent Z, Blanchard A, Davie JR, McManus K, Murphy LC, Myal Y, Leygue E. FEBS Lett. 2015 Nov 17. pii: S0014-5793(15)00978-3. doi: 10.1016/j.febslet.2015.11.007. [Epub ahead of print] PubMed PMID: 26581859. Estrogen regulates luminal progenitor cell differentiation through H19 gene expression. Basak P, Chatterjee S, Weger S, Bruce MC, Murphy LC, Raouf A. Endocr Relat Cancer. 2015 Aug;22(4):505-17. doi: 10.1530/ERC-15-0105. Epub 2015 May 5. Intratumoural inflammation and endocrine resistance in breast cancer. Murray JI, West NR, Murphy LC, Watson PH. Endocr Relat Cancer. 2015 Feb;22(1):R51-67. doi: 10.1530/ERC-14-0096. Epub 2014 Nov 17. Review. A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer. Vollan HK, Rueda OM, Chin SF, Curtis C, Turashvili G, Shah S, Lingjærde OC, Yuan Y, Ng CK, Dunning MJ, Dicks E, Provenzano E, Sammut S, McKinney S, Ellis IO, Pinder S, Purushotham A, Murphy LC, Kristensen VN; METABRIC Group, Brenton JD, Pharoah PD, Børresen-Dale AL, Aparicio S, Caldas C. Mol Oncol. 2015 Jan;9(1):115-27. doi: 10.1016/j.molonc.2014.07.019. Epub 2014 Aug 8. The kinome associated with estrogen receptor-positive status in human breast cancer. Bruce MC, McAllister D, Murphy LC. Endocr Relat Cancer. 2014 Oct;21(5):R357-70. doi: 10.1530/ERC-14-0232. Epub 2014 Jul 23. Review. The Mammalian Target for Rapamycin Pathway is Associated with the Phosphorylation Score (P7) for Estrogen Receptor-a in Human Breast Tumors, in vivo. (2014) Anuraag Shrivastav, M Chrissie Bruce, Danira Jaksic, Tarek Bader, Sri Seekallu, Carla Penner, Zoann Nugent, Peter Watson, Leigh Murphy. Breast Cancer Res 16(3):R49 Certification for Biobanks: The Program Developed by the Canadian Tumour Repository Network (CTRNet). A. Matzke, S. O'Donoghue, R.O. Barnes, H. Daudt, S. Cheah, A. Suggitt, J. Bartlett, S. Damaraju, R. Johnston, L. Murphy, L. Shepherd, A.M. Mes-Masson, B. Schacter, P. Watson. (2012) Biopreservation and Biobanking 10/5 : 426-432. A Framework for Biobank Sustainability. Peter H. Watson, Sara Y. Nussbeck, Candace Carter, Sheila O'Donoghue, Stefanie Cheah, Rebecca Barnes, John Bartlett, Jane Carpenter, William Grizzle, Randy Johnston, Anne-Marie Mes-Masson, Leigh Murphy, Katherine Sexton, Lois Shepherd, Daniel Simeon-Dubach, Nik Zeps, Brent Schacter. (2014) Biopreservation and Biobanking (in press) splice variant expression in four large cohorts of human breast cancer patient tumors.Breast Wimberly H, Han G, Pinnaduwage D, Murphy LC, Yang XR, Andrulis IL, Sherman M, Figueroa J, Rimm DL. ERß Cancer Res Treat. 2014 Jul 10. [Epub ahead of print] Preferential Estrogen Receptor ß Ligands Reduce Bcl-2 Expression in Hormone-Resistant Breast Cancer Cells to Increase Autophagy.Ruddy SC, Lau R, Cabrita MA, McGregor C, McKay BC, Murphy LC, Wright JS, Durst T, Pratt MA. Mol Cancer Ther. 2014 Jul;13(7):1882-93. doi: 10.1158/1535-7163.MCT-13-1066. Epub 2014 Apr 30. Steroid receptor RNA activator protein (SRAP) expression as a prognostic factor in ER+ human breast tumors. Yan Y, Penner CC, Skliris GP, Cooper C, Nugent Z, Blanchard A, Hamedani MK, Wang X, Myal Y, Murphy LC, Leygue E. J Cancer Res Clin Oncol. 2013 Aug 2. [Epub ahead of print] Claudin 1 expression in basal-like breast cancer is related to patient age. Blanchard AA, Ma X, Dueck KJ, Penner C, Cooper SC, Mulhall D, Murphy LC, Leygue E, Myal Y. BMC Cancer. 2013 May 30;13:268. doi: 10.1186/1471-2407-13-268. Expression of both Estrogen Receptor-beta 1 (ER-ß1) and its co-regulator Steroid Receptor RNA Activator Protein (SRAP) are predictive for benefit from tamoxifen therapy in patients with Estrogen Receptor-alpha (ER-a)-Negative Early Breast Cancer (EBC). Yan Y, Li X, Blanchard A, Bramwell VH, Pritchard KI, Tu D, Shepherd L, Myal Y, Penner C, Watson PH, Leygue E, Murphy LC. Ann Oncol. 2013 Aug;24(8):1986-93. doi: 10.1093/annonc/mdt132. Epub 2013 Apr 11. A bi-faceted role of estrogen receptor ß in breast cancer. Leygue E, Murphy LC. Endocr Relat Cancer. 2013 May 30;20(3):R127-39. doi: 10.1530/ERC-12-0389. Print 2013 Jun. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Gräf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S; METABRIC Group, Langerød A, Green A, Provenzano E, Wishart G, Pinder S, Watson P, Markowetz F, Murphy L, Ellis I, Purushotham A, Børresen-Dale AL, Brenton JD, Tavaré S, Caldas C, Aparicio S. Nature.(2012) Apr 18;486(7403):346-52. Post-translational modifications of nuclear receptors and human disease. Anbalagan M, Huderson B, Murphy L, Rowan BG.(2012) Nucl Recept Signal. 2012;10:e001. Epub 2012 Feb 27. Review The role of estrogen receptor-ß in breast cancer.Murphy LC, Leygue E.(2012) Semin Reprod Med. 2012 Jan;30(1):5-13. Epub 2012 Jan 23. Review. Oncostatin M suppresses oestrogen receptor-a expression and is associated with poor outcome in human breast cancer. West NR, Murphy LC, Watson PH.(2012) Endocr Relat Cancer. 2012 Apr 10;19(2):181-95. Print 2012 Apr. CARM1 is an important determinant of ERa-dependent breast cancer cell differentiation and proliferation in breast cancer cells.Al-Dhaheri M, Wu J, Skliris GP, Li J, Higashimato K, Wang Y, White KP, Lambert P, Zhu Y, Murphy L, Xu W.(2011) Cancer Res. 2011 Mar 15;71(6):2118-28. Epub 2011 Jan 31. Clinical significance of estrogen receptor phosphorylation. Murphy LC, Seekallu SV, Watson PH.(2011) Endocr Relat Cancer. 2011 Jan 19;18(1):R1-14. Print 2011 Feb. Review. Identification of CARM1 as an important determinant of ERa-dependent breast cancer cell differentiation and proliferation. Mariam Al-Dhaheri, George Skliris, Jiacai Wu, Jun Li, Ken Higashimato, Yidan Wang, Kevin White, Yuerong Zhu, Leigh Murphy, Wei Xu. (2011) Cancer Res71(6):2118-28